pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,105 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1156Endpoints875BioPharma Dive339BioSpace293Fierce Biotech277onclive165raps104globenewswire health73
therapy area
allOncology7353Rare Disease1826Cardiology1672Immunology1456Hematology1302Vaccines1173Pulmonology
  • Faro AI secures $37M Series B to accelerate clinical trials with artificial intelligence
    Faro AI, a San Diego‑based startup, announced a $37 million Series B financing round aimed at expanding its artificial‑intelligence platform. The new funding will be directed toward developing too…
    Endpoints · 12d agoDealPositive↗ source
  • Akeso reports phase 3 overall survival win for ivonescimab in advanced biliary tract cancer
    Akeso announced that its bispecific antibody ivonescimab combined with chemotherapy improved overall survival in a China phase 3 trial for advanced biliary tract cancer, beating the standard regime…
    Fierce Biotech · 12d agoPositive readoutPositive↗ source
← prev
page 13 of 125
next →
fda recalls67
fda medwatch60
fda press38
1084
Psychiatry & CNS858
Ophthalmology491
Pain469
Endocrinology & Metabolism466
Infectious Disease437
  • FDA grants three-month extension for Capricor's Duchenne muscular dystrophy cell therapy review
    The FDA has granted a three‑month extension to Capricor Therapeutics' review of its cell therapy for Duchenne muscular dystrophy after the original PDUFA date passed. The decision follows a content…
    BioSpace · 12d agoRegulatoryNeutral↗ source
  • Deloitte urges advanced therapy makers to adopt AI-driven digital staff to overcome operational bandwidth limits
    Advanced therapy manufacturers are confronting an operational bottleneck as their pipelines expand rapidly. More than a thousand advanced therapies are in development and the U.S. patient pool is e…
    Fierce Biotech · 12d agoNeutral↗ source
  • Profit motive highlighted as key to advancing women’s health research and boosting economic productivity
    Experts say that turning to the profit motive could spur investment in under‑funded women’s health areas such as endometriosis, osteoporosis and autoimmune disorders. They note a long history of r…
    STAT · 12d agoNeutral↗ source
  • FDA clears Abbott’s Libre Duo 10-Day sensor to warn of diabetic ketoacidosis
    The U.S. Food and Drug Administration has cleared Abbott’s new wearable device that measures both glucose and ketone levels in people with diabetes. The clearance allows the product to be marketed…
    Fierce Biotech · 12d agoApprovalPositive↗ source
  • Boston Scientific reports cyberattack that disrupts operations and order processing
    Boston Scientific disclosed in an SEC filing on Aug. 26 that it detected a cybersecurity incident the previous day, marking the latest medtech cyberattack of the year. The breach impacted several…
    Fierce Biotech · 12d agoNegative↗ source
  • CDMO hiring struggles as demand for specialized talent outpaces supply
    Contract development and manufacturing organizations are finding it harder to fill positions, according to a search expert who tracks life-science talent. The surge in outsourcing has created a gap…
    BioSpace · 12d agoNeutral↗ source
  • Kennedy spreads vaccine misinformation as measles deaths spark heated call with Pennsylvania governor
    After Pennsylvania health officials reported two deaths among unvaccinated individuals from measles, HHS Secretary Robert F. Kennedy Jr. phoned Governor Josh Shapiro to discuss federal assistance.…
    STAT · 12d agoNegative↗ source
  • UCSF maps over 1,800 protein interactions linked to autism, revealing new drug target opportunities
    UCSF scientists created a molecular map of autism by analyzing 100 risk genes, which uncovered more than 1,800 protein-protein interactions. The study found that about 87% of these connections had…
    Fierce Biotech · 12d agoPositive↗ source
  • Key data on lipoprotein(a)-targeting cardiovascular drugs expected soon
    A STAT+ newsletter highlights that several major pharmaceutical firms are developing drugs that lower lipoprotein(a), a particle linked to heart disease. The companies view Lp(a) reduction as a po…
    STAT · 12d agoNeutral↗ source
  • Insitro CEO Daphne Koller discusses using AI to accelerate clinical trials
    STAT+ AI Prognosis newsletter featured an interview with Insitro chief executive Daphne Koller about the role of artificial intelligence in drug discovery and how it could speed up clinical trials.…
    STAT · 12d agoNeutral↗ source
  • Two Unvaccinated Pennsylvania Residents Die from Measles, First US Measles Deaths in 2026
    The Pennsylvania Department of Health reported two measles-associated deaths in the state. Both individuals were unvaccinated, making these the first measles deaths in the United States for 2026 an…
    STAT · 12d agoNeutral↗ source
  • Spyre Therapeutics deprioritizes anti-TL1A rheumatoid arthritis candidate after modest Phase 2 results
    Spyre Therapeutics said on Tuesday it will shift resources away from its anti-TL1A antibody that was being developed for rheumatoid arthritis. The decision follows the Phase 2 study, which showed…
    Endpoints · 12d agoNegative readoutNegative↗ source
  • Oxford study finds Shingrix linked to lower risk of heart attacks, strokes and heart failure
    Researchers at Oxford University reported that receiving the newer shingles vaccine Shingrix was associated with a reduced risk of cardiovascular disease. The observation follows earlier work by t…
    STAT · 12d agoPositive readoutNeutral↗ source
  • Inside the Gulf biotech deal model, ahead of RGMBS 2026 in Riyadh
    Sovereign capital, guaranteed offtake, and localization mandates are reshaping how biotech deals get structured in the Gulf, ahead of the Riyadh Global Medical Biotechnology Summit (RGMBS) 2026, 14…
    BioSpace · 12d agoDealNeutral↗ source
  • BioSpace launches dashboard to track performance of U.S. biotech IPOs in 2026
    BioSpace introduced a new IPO dashboard that monitors U.S. biotech companies that went public in 2026. The tool will be refreshed weekly with the latest closing prices and will add any newly liste…
    BioSpace · 12d agoNeutral↗ source
  • Cellares defends its cell therapy platform after Bristol Myers ends partnership
    Cellares, a cell therapy manufacturing startup, responded to criticism from Bristol Myers Squibb after the drugmaker terminated their agreement. Bristol Myers withdrew, saying Cellares' commercial…
    Endpoints · 12d agoNegative↗ source
  • Calcium scans may guide statin decisions in a few borderline patients, studies find
    Two recent trials evaluated whether coronary artery calcium (CAC) scans, used together with the PREVENT risk calculator, can help decide on statin therapy. The studies compared the imaging results…
    STAT · 12d agoNeutral↗ source
  • FDA reportedly weighing two new deputy commissioner roles, one for health AI and one for drugs
    The Food and Drug Administration is said to be considering the creation of two additional deputy commissioner positions. The proposal is being reported by media outlets but has not been confirmed b…
    BioSpace · 12d agoRegulatoryNeutral↗ source
  • Biotech entrepreneur Someit Sidhu launches JATT III Acquisition SPAC with $60M Nasdaq IPO
    Someit Sidhu, M.D., announced the formation of JATT III Acquisition, a new special purpose acquisition company that raised $60 million in an initial public offering on Nasdaq. The SPAC will seek t…
    Fierce Biotech · 12d agoDealNeutral↗ source
  • New York law adds recording safeguard to medical aid in dying, sparking ethical debate
    New York has enacted a law that permits terminally ill residents with six months or less to obtain medication for self-directed death. A distinctive feature of the legislation is that patients must…
    STAT · 12d agoRegulatoryNeutral↗ source
  • Many post-Dobbs abortion concerns have not materialized, says expert
    David N. Hackney, a professor of reproductive biology and division chief of maternal‑fetal medicine, reflects on the four years since the Supreme Court overturned Roe v. Wade. He notes that several…
    STAT · 12d agoNeutral↗ source
  • FDA expands Jazz's Ziihera to frontline HER2-positive gastroesophageal cancers, unlocking $1.5 billion market
    The U.S. Food and Drug Administration has broadened the approved use of Jazz Pharmaceuticals' cancer therapy Ziihera. The drug can now be given as an initial treatment for patients with HER2‑positi…
    BioPharma Dive · 13d agoApprovalPositive↗ source
  • FDA expands Jazz's Ziihera use to frontline gastric cancer
    FDA granted approval for Jazz Pharmaceuticals' bispecific antibody Ziihera as a frontline treatment for certain gastric cancer patients. This is the first time Ziihera will be marketed to newly di…
    Endpoints · 13d agoApprovalPositive↗ source